The Atlas Arteria Group (ASX: ALX) share price is in focus today after the company reported Q3 2026 proportional toll revenue down 0.4% on the prior year, while reported revenue slid 8.9% due to foreign exchange impacts.

What did Atlas Arteria report?

• Q3 2026 proportional toll revenue down 0.4% excluding FX, reported revenue down 8.9%
• APRR (France) traffic fell 3.5%, toll revenue down 1.7%
• Chicago Skyway (US) traffic up 6.4%, toll revenue up 9.6%
• Dulles Greenway (US) traffic up 3.7%, toll revenue up 3.9%
• A79 (France) traffic up 0.7%, toll revenue up 3.4%
• Warnow Tunnel (Germany) traffic up 2.2%, toll revenue up 4.2%

What else do investors need to know?

The French Government has proposed potential changes to transport infrastructure taxes in its draft 2027 Budget Bill. If these increases go ahead, they could significantly raise costs for the APRR Group, with a €210 million estimated impact based on 2025 figures. The final details and timing depend on when the bill is enacted by the French Parliament.

High fuel prices continued to weigh on French light vehicle traffic during the quarter. In contrast, Atlas Arteria’s US and German operations saw solid traffic growth, helped by roadworks diverting vehicles onto its routes and stable macroeconomic conditions.

Toll price increases are planned in both Germany (Warnow Tunnel) from November 2026 and the US (Chicago Skyway) from January 2027, which could support future revenue streams.

What’s next for Atlas Arteria?

Atlas Arteria will update investors once the outcome of the French Budget Bill debate is known, as these tax changes could impact future profitability. The company continues to monitor fuel price movements in France and expects continued growth in the US and Germany, especially as roadworks keep bolstering traffic numbers.

Planned toll increases on key assets are set to take effect in coming months, which may help offset softer performance in France. Atlas Arteria emphasises its ongoing commitment to long-term value through disciplined management and sustainable practices.

Atlas Arteria share price snapshot

Over the past 12 months, Atlas Arteria shares have declined 25%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 3% over the same period.

View Original Announcement

The post Atlas Arteria Q3 2026: US assets drive growth as French revenue slows appeared first on The Motley Fool Australia.

More reading

• How much is needed in superannuation to target $80,000 a year in passive income?
• 2 ASX dividend shares with yields above 8%
• Aurizon Holdings vs Atlas Arteria: Which ASX 200 high-yield share wins for reliable passive income?
• 3 great ASX dividend shares with 7%+ yields
• How much is needed in superannuation to target $2,000 a week in passive income

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

If you are in the market for some new portfolio additions, it could be worth seeing what the team at Morgans is saying about the three ASX shares in this article. 

Does the broker rate them as buys, holds, or sells? Let’s find out:

Deep Yellow Ltd (ASX: DYL)

Morgans highlights that this uranium developer’s final investment decision (FID) for the Tumas project is behind schedule due to uncertain equity market and funding conditions.

Nevertheless, it remains positive and sees an opportunity for investors with a higher tolerance for risk to buy its shares. It has retained its speculative buy rating with a reduced price target of $1.50. Morgans said:

DYL has withdrawn its targeted 4Q26 Final Investment Decision (FID) for Tumas, citing weakness in equity market conditions and a constrained funding backdrop for uranium developers. The FID deferral is not entirely surprising given the weakness in DYL’s share price over recent months. In our view, raising equity at current levels would have represented an unattractive funding outcome for existing shareholders. 

Importantly, we view this as a delay rather than a change in strategy, with DYL remaining focused on advancing Tumas and positioning the project for a future FID. We maintain our rating of SPECULATIVE BUY with a price target of A$1.50ps (previously A$1.95ps).

PLS Group Ltd (ASX: PLS)

One ASX share that has made an FID this month is lithium miner PLS. 

The decision was a touch mixed with higher capital expenditure but also higher steady-state production. As a result, the broker has retained its accumulate rating on PLS shares with a $3.70 price target. It said:

PLS has taken FID on the ~A$1.9bn P2000 expansion, lifting capacity to ~2Mtpa (from ~1.2Mtpa) with first production targeted in 1Q FY30. P2000 capex is ~20% above MorgansF, but steady-state production is higher (+16%) and sustaining + mine development spend lower (-14%). Maintain ACCUMULATE with A$3.70ps target price.

Pro Medicus Ltd (ASX: PME)

Now could be a good time to buy Pro Medicus shares according to Morgans.

In response to a new contract win, the broker has upgraded its shares to a buy rating with a $230.00 price target. It commented:

PME has announced a further seven-year, A$24m full stack cloud contract with Billings Clinic Logan Health, its third new community health system win in FY27 to date (A$72m TCV, A$10.3m new ARR). The FY27 wins are modest individually but consistent in size, term and scope, pointing to a repeatable mid-market playbook that broadens the pipeline beyond large Integrated Delivery Networks. 

Near-term focus shifts to RSNA in late November as the likely window for a larger deal, and to execution on a busy 1Q’CY27 go-live schedule underpinning FY28. We upgrade to a BUY (from Accumulate), with no change to our A$230 target price.

The post Buy, hold, sell: Deep Yellow, PLS, Pro Medicus shares appeared first on The Motley Fool Australia.

More reading

• Pro Medicus: $43m US contract boosts outlook
• 5 things to watch on the ASX 200 on Wednesday
• 2 ASX stocks down 28% to 30% in a month I’d buy right now
• 3 ASX mining shares to buy with 30% to 129% upside ahead: experts
• This ASX uranium company is set to surge: Brokers

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Northern Star Resources Ltd (ASX: NST) share price is in focus today after the company reported September quarter gold sales of 364,000 ounces at an all-in sustaining cost (AISC) of A$3,217 per ounce, with net mine cash flow of A$210 million.

What did Northern Star Resources report?

• Gold sold: 363,891 ounces for the quarter
• All-in sustaining cost (AISC): A$3,217/oz (US$2,244/oz)
• Net mine cash flow: A$210 million (all three centres positive)
• Group underlying free cash flow: negative A$31 million (including A$113 million tax payments)
• Cash and bullion as at 30 September: A$1,200 million
• FY27 production guidance unchanged: 1,500–1,650koz gold sold at AISC of A$3,050–3,450/oz

What else do investors need to know?

Northern Star completed the KCGM mill tie-in during the September quarter, with commissioning of the expanded plant now underway. This milestone is key for the group’s long-term production plans, though mill ramp-up affected grades and recoveries for the quarter.

All three production centres—Kalgoorlie, Yandal, and Pogo—delivered positive cash flow. The company invested A$56 million in exploration, while the Hemi Project studies are progressing to plan towards a final investment decision late in FY27.

Northern Star’s balance sheet remains strong, with A$1.2 billion in cash and bullion and bank facilities in place. The company utilised A$500 million of these facilities post quarter-end to help maintain targeted cash levels ahead of a dividend payment.

What did Northern Star Resources management say?

Suresh Vadnagra, Managing Director & CEO, commented:

The September quarter has delivered another major milestone for Northern Star with completion of the KCGM mill tie-in and commencement of commissioning of the integrated plant. Commissioning is progressing in line with expectations for this early stage. We have also had a solid start to FY27 across our operations, with all sites delivering in line with plan. While I still have a lot to learn about our individual assets, we have a high-quality asset base and a strong foundation on which to grow. Consistent delivery will be fundamental to our success and will require strong operating discipline, clear accountability and a group-wide focus on costs, execution and capital discipline. My immediate priority is to understand the business in parallel with focusing on completing the KCGM mill expansion safely and efficiently as well as ensuring consistent delivery across the portfolio.

What’s next for Northern Star Resources?

FY27 production guidance is unchanged, with the company aiming for up to 1.65 million ounces of gold sold at lower costs over the year. Production is expected to be weighted to the second half, as the expanded KCGM plant ramps up.

Northern Star is focused on cost discipline, capital management, and advancing its growth projects, including Stage II of the KCGM expansion and the Hemi Project. Management says a portion of FY27’s capital expenditure remains discretionary, giving flexibility should operating conditions change.

Northern Star Resources share price snapshot

Over the past 12 months, Northern Star Resources shares have declined 5%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 3% over the same period.

View Original Announcement

The post Northern Star Resources posts production and commissioning update appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Wednesday
• 5 things to watch on the ASX 200 on Monday
• 5 things to watch on the ASX 200 on Thursday
• 5 things to watch on the ASX 200 on Wednesday
• 3 dirt cheap ASX shares I think are undervalued today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.